

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus DHPPI/L4R lyophilisate and suspension for suspension for injection.

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each dose of 1 ml contains:

Active substances:

Lyophilisate (live attenuated):

	Minimum	Maximum
Canine distemper virus	$10^{3.1}$ TCID ₅₀	$10^{5.1}$ TCID ₅₀
Canine adenovirus Type 2	$10^{3.6}$ TCID ₅₀	$10^{5.3}$ TCID ₅₀
Canine parvovirus Type 2b	$10^{4.3}$ TCID ₅₀	$10^{6.6}$ TCID ₅₀
Canine parainfluenza virus Type 2	$10^{3.1}$ TCID ₅₀	$10^{5.1}$ TCID ₅₀

Suspension (inactivated):

<i>L. interrogans</i> serovar Icterohaemorrhagiae	ALR titre \geq 1:51
<i>L. interrogans</i> serovar Canicola	ALR titre \geq 1:51
<i>L. kirschneri</i> serovar Grippotyphosa	ALR titre \geq 1:40
<i>L. interrogans</i> serovar Bratislava	ALR titre \geq 1:51
Rabies virus	\geq 5 IU

Adjuvant:

Aluminium hydroxide	1.8–2.2 mg.
---------------------	-------------

3. PACKAGE SIZE

25 x 1 dose

50 x 1 dose

4. TARGET SPECIES

Dogs.

5. INDICATION(S)

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Keep the vials in the outer carton.

Store and transport refrigerated.

Do not freeze.

Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

14. MARKETING AUTHORISATION NUMBERS

Vm 42058/5081

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

Accidental injection is dangerous.

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read the package leaflet.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

POM-V

To be supplied only on veterinary prescription.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {1 dose lyophilisate}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus DHPPi/L4R lyophilisate



**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE
SUBSTANCE(S)**

DHPPi

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once reconstituted use immediately.

5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 dose

6. ROUTE(S) OF ADMINISTRATION

SC

7. WITHDRAWAL PERIOD

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {1 ML SUSPENSION}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus DHPPI/L4R suspension



**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE
SUBSTANCE(S)**

L4R

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

1 ml

6. ROUTE(S) OF ADMINISTRATION

SC

7. WITHDRAWAL PERIOD

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versican Plus DHPPI/L4R lyophilisate and suspension for suspension for injection for dogs

2. COMPOSITION

Each dose of 1 ml contains:

Active substances:

Lyophilisate (live attenuated):

	Minimum	Maximum
Canine distemper virus, strain CDV Bio 11/A	10 ^{3.1} TCID ₅₀ *	10 ^{5.1} TCID ₅₀ *
Canine adenovirus Type 2, strain CAV-2 Bio 13	10 ^{3.6} TCID ₅₀ *	10 ^{5.3} TCID ₅₀ *
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B	10 ^{4.3} TCID ₅₀ *	10 ^{6.6} TCID ₅₀ *
Canine parainfluenza Type 2 virus, strain CPIV-2 Bio 15	10 ^{3.1} TCID ₅₀ *	10 ^{5.1} TCID ₅₀ *

Suspension (inactivated):

<i>Leptospira interrogans</i> serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089	ALR** titre ≥ 1:51
<i>Leptospira interrogans</i> serogroup Canicola serovar Canicola, strain MSLB 1090	ALR** titre ≥ 1:51
<i>Leptospira kirschneri</i> serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091	ALR** titre ≥ 1:40
<i>Leptospira interrogans</i> serogroup Australis serovar Bratislava, strain MSLB 1088	ALR** titre ≥ 1:51
Rabies virus, strain SAD Vnukovo-32	≥ 5 IU***

* Tissue culture infectious dose 50%.

** Antibody micro agglutination-lytic reaction.

*** International units.

Adjuvant:

Aluminium hydroxide 1.8–2.2 mg.

The visual appearance is as follows:

Lyophilisate: spongy matter of white colour.

Suspension: pink colour with fine sediment.

3. TARGET SPECIES

Dogs.

4. INDICATIONS FOR USE

Active immunisation of dogs from 8–9 weeks of age:

- to prevent mortality and clinical signs caused by canine distemper virus,
- to prevent mortality and clinical signs caused by canine adenovirus type 1,
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,
- to prevent clinical signs, leucopenia and viral excretion caused by canine parvovirus,
- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,
- to prevent clinical signs, infection and urinary excretion caused by *L. interrogans* serogroup Australis serovar Bratislava,
- to prevent clinical signs and urinary excretion and reduce infection caused by *L. interrogans* serogroup Canicola serovar Canicola and *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae,
- to prevent clinical signs and reduce infection and urinary excretion caused by *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa and
- to prevent mortality, clinical signs and infection caused by rabies virus.

Onset of immunity:

- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after the first vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after the completion of primary course for *Leptospira* components.

Duration of immunity:

At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies. The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years. At least one year following the primary vaccination course for canine parainfluenza virus and *Leptospira* components. Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.

5. CONTRAINDICATIONS

None.

6. SPECIAL WARNING(S)

Special warnings:

A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Immunological responses to the CDV, CAV and CPV components of the vaccine may be delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions. In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.

The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10 days. However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs and domestic cats. The vaccine virus strain CPV-2b has not been tested in other carnivores (except dogs and domestic cats) that are known to be susceptible to canine parvoviruses and therefore vaccinated dogs should be separated from them after vaccination.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse events other than those mentioned in section 7 (Adverse events) were observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. ADVERSE EVENTS

Dogs:

Common (1 to 10 animals / 100 animals treated):
injection site swelling ¹
Rare (1 to 10 animals / 10,000 animals treated):
hypersensitivity reaction ² (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis

¹A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

²If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first

instance, your veterinarian. You can also report any adverse events <to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or> via your national reporting system.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

Primary vaccination scheme:

Two doses of Versican Plus DHPPi/L4R 3–4 weeks apart from 8–9 weeks of age. The second dose should not be given before 12 weeks of age.

Rabies:

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. Therefore, the first dose may be given using Versican Plus DHPPi/L4. In this case the second vaccination with Versican Plus DHPPi/L4R should not be given before 12 weeks.

However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside the EU/UK, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).

In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6-week old dogs.

Re-vaccination scheme:

A single dose of Versican Plus DHPPi/L4R should be given every 3 years. Annual re-vaccination is required for Parainfluenza and *Leptospira* components. Therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.

9. ADVICE ON CORRECT ADMINISTRATION

Aseptically reconstitute the lyophilisate with suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Appearance of the reconstituted vaccine: pink/red, or yellowish colour with light opalescence.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42058/5081

Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of suspension.

Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of suspension.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey, KT22 7LP
UK
Tel: +44 (0) 345 300 8034

Manufacturer responsible for batch release:

Bioveta a.s.
Komenskeho 212/12
683 23 Ivanovice Na Hane
Czechia

Local representatives and contact details to report suspected adverse reactions:

United Kingdom (Great Britain)

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey, KT22 7LP
UK
Tel: +44 (0) 345 300 8034

United Kingdom (Northern Ireland)

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey, KT22 7LP
UK
Tel: +44 (0) 345 300 8034

17. OTHER INFORMATION

The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, *Leptospira interrogans* serogroup Australis serovar Bratislava, *Leptospira interrogans* serogroup Canicola serovar Canicola, *Leptospira kirschneri* serogroup Grippotyphosa serovar Grippotyphosa, *Leptospira interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.

Gavin Hall
Approved: 19 March 2025